FY2025 EPS Estimate for ADC Therapeutics Boosted by Analyst

ADC Therapeutics SA (NYSE:ADCT) – Analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of ADC Therapeutics in a research report issued on Thursday, May 15th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will earn ($1.99) per share for the year, up from their prior forecast of ($2.25). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for ADC Therapeutics’ current full-year earnings is ($1.69) per share.

ADC Therapeutics (NYSE:ADCT) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $23.03 million for the quarter, compared to the consensus estimate of $17.71 million.

Several other equities research analysts have also issued reports on ADCT. Stephens lifted their price target on shares of ADC Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. Guggenheim lowered their target price on ADC Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, March 31st. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of ADC Therapeutics in a report on Monday, March 31st. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $8.00 price target on shares of ADC Therapeutics in a research note on Thursday, May 15th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $7.75.

ADC Therapeutics Stock Performance

Shares of ADCT opened at $2.15 on Monday. The firm has a market cap of $212.74 million, a P/E ratio of -0.90 and a beta of 1.54. ADC Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.17. The firm’s 50 day moving average price is $1.43 and its two-hundred day moving average price is $1.80.

Institutional Investors Weigh In On ADC Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Kazazian Asset Management LLC acquired a new position in shares of ADC Therapeutics during the fourth quarter valued at about $26,000. Two Sigma Securities LLC purchased a new stake in ADC Therapeutics in the fourth quarter worth $30,000. Russell Investments Group Ltd. raised its stake in ADC Therapeutics by 122.6% in the 4th quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company’s stock valued at $33,000 after acquiring an additional 9,248 shares during the period. Prudential Financial Inc. bought a new stake in shares of ADC Therapeutics in the fourth quarter valued at approximately $35,000. Finally, Cerity Partners LLC purchased a new stake in shares of ADC Therapeutics during the first quarter worth $25,000. 41.10% of the stock is currently owned by institutional investors.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.